Skip to main content

Rubin Gary D's Form 4 filing

bioAffinity Technologies, Inc. (BIAF) · filed Oct 21, 2022

Accession no.
0001493152-22-029376
Filed
Oct 21, 2022, 6:50 PM ET
Trade date
Jul 20-Sep 6, 2022
Filing delay
93 daysLate
Rule 10b5-1 plan
Not on the form (before 2023)

This filing lists 8 non-derivative transactions and 13 derivative transactions. It was filed 93 days after the trade, past the 2-business-day deadline.

Reporting owners

A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.

Reporting owners on this filing
OwnerRelationship to the company
Rubin Gary DCIK 0001947569Director, 10% Owner
Harvey Sandler Revocable TrustCIK 000132325310% Owner

Non-derivative securities (Table I)

Acquisitions and disposals of common stock and similar shares, one row per line on the filing.

Non-derivative transactions
Trade dateSecurityTransactionSharesPriceValueShares afterOwnershipFlags
Sep 6, 2022Common StockCConversionAcquired+15,876$4.20F4+$66,679.251,590Direct
Sep 6, 2022Common StockCConversionAcquired+266,850$4.20F5+$1,120,7701,082,866Indirect
Sep 6, 2022Common StockCConversionAcquired+38,287$4.20F6+$160,805.41,121,153Indirect
Sep 6, 2022Common StockCConversionAcquired+93,821$4.20F7+$394,048.21,214,974Indirect
Sep 6, 2022Common StockCConversionAcquired+63,958$4.20F8+$268,623.61,278,932Indirect
Sep 6, 2022Common StockCConversionAcquired+58,577$4.20F9+$246,023.41,337,509Indirect
Sep 6, 2022Common StockCConversionAcquired+230,309$5.17F10+$1,190,697.531,567,818Indirect
Aug 31, 2022Common StockPPurchaseAcquired+16,326–F11–1,584,144Indirect

Derivative securities (Table II)

Options, warrants, restricted stock units and similar. Shares are the underlying shares; price and value are for the derivative itself, and the holding after is in derivative units.

Derivative transactions
Trade dateSecurityTransactionUnderlying sharesUnit priceValueHeld afterOwnershipFlags
Sep 6, 2022Common StockCConversionDisposed−15,876$0.00–0Direct
Sep 6, 2022Common StockCConversionDisposed−266,850$0.00–0Indirect
Sep 6, 2022Common StockCConversionDisposed−38,287$0.00–0Indirect
Sep 6, 2022Common StockCConversionDisposed−93,821$0.00–0Indirect
Sep 6, 2022Common StockCConversionDisposed−63,958$0.00–0Indirect
Sep 6, 2022Common StockCConversionDisposed−58,577$0.00–0Indirect
Sep 6, 2022Common StockCConversionDisposed−230,309$0.00$00Indirect
Aug 31, 2022Common StockPPurchaseAcquired+16,326–F11–16,326Indirect
Aug 31, 2022Common StockPPurchaseAcquired+16,326–F11–16,326Indirect
Sep 6, 2022Common StockAGrant or awardAcquired+12,241–F12–12,241Direct
Sep 6, 2022Common StockPPurchaseAcquired+408,125–F13–408,125Indirect
Jul 20, 2022Common StockAGrant or awardAcquired+4,896–F14–4,896Direct
Jul 20, 2022Common StockPPurchaseAcquired+163,248–F15–163,248Indirect

Footnotes and remarks

Livermore keeps the footnotes that transaction prices refer to, all footnotes of amendments (Form 4/A) and the filing's remarks. Other footnotes, such as how indirect holdings are held or the details of a trading plan, are only in the original on SEC EDGAR.

F4

In connection with the closing of the Issuer's IPO (the "IPO Closing") on September 6, 2022, the $66,682.86 of outstanding principal and accrued but unpaid interest of this secured convertible promissory note (a "Note"), dated December 21, 2018, automatically converted into 15,876 shares of Common Stock at a conversion price of $4.20 per share (on a Common Stock equivalent basis).

Referenced by the price of 1 transaction in Table I.

F5

In connection with the IPO Closing on September 6, 2022, the $1,120,773.84 of outstanding principal and accrued but unpaid interest of this Note, dated December 21, 2018, automatically converted into 266,850 shares of Common Stock at a conversion price of $4.20 per share (on a Common Stock equivalent basis).

Referenced by the price of 1 transaction in Table I.

F6

In connection with the IPO Closing on September 6, 2022, the $160,808.22 of outstanding principal and accrued but unpaid interest of this Note, dated February 7, 2019, automatically converted into 38,287 shares of Common Stock at a conversion price of $4.20 per share (on a Common Stock equivalent basis).

Referenced by the price of 1 transaction in Table I.

F7

In connection with the IPO Closing on September 6, 2022, the $394,048 of outstanding principal and accrued but unpaid interest of this Note, dated April 18, 2019, automatically converted into 93,821 shares of Common Stock at a conversion price of $4.20 per share (on a Common Stock equivalent basis).

Referenced by the price of 1 transaction in Table I.

F8

In connection with the IPO Closing on September 6, 2022, the $268,626.30 of outstanding principal and accrued but unpaid interest of this Note, dated July 26, 2019, automatically converted into 63,958 shares of Common Stock at a conversion price of $4.20 per share (on a Common Stock equivalent basis).

Referenced by the price of 1 transaction in Table I.

F9

In connection with the IPO Closing on September 6, 2022, the $246,027.40 of outstanding principal and accrued but unpaid interest of this Note, dated October 22, 2019, automatically converted into 58,577 shares of Common Stock at a conversion price of $4.20 per share (on a Common Stock equivalent basis).

Referenced by the price of 1 transaction in Table I.

F10

In connection with the IPO Closing on September 6, 2022, the 1,612,163 shares of Series A Preferred Stock owned by the Trust automatically converted at the then-effective 1-for-7 conversion rate into 230,309 fully paid and nonassessable shares of Common Stock. The Series A Preferred Stock had no expiration date.

Referenced by the price of 1 transaction in Table I.

F11

The reported securities are included within 16,326 Units purchased by the Trust for $6.125 per Unit in the Issuer's IPO. Each Unit consists of one share of Common Stock, one tradeable warrant to purchase one share of Common Stock at an exercise price of $7.35 per share, and one five-year non-tradeable warrant to purchase one share of Common Stock at an exercise price of $7.656 per share.

Referenced by the price of 1 transaction in Table I and 2 transactions in Table II.

F12

Represents a right to purchase 12,241 shares of Common Stock underlying a warrant that became initially exercisable in connection with the IPO Closing on September 6, 2022 at an exercise price equal to the IPO price of $6.125 per share. The warrant was issued to Mr. Rubin on August 25, 2021 as consideration for his agreement to enter into an amendment to that certain Secured Convertible Note Purchase Agreement, dated December 21, 2018, as amended (the "Note Purchase Agreement") to extend the maturity date of the Note issued to him under the Note Purchase Agreement from December 31, 2021 to May 31, 2022.

Referenced by the price of 1 transaction in Table II.

F13

Represents a right to purchase an aggregate of 408,125 shares of Common Stock underlying five warrants that became initially exercisable in connection with the IPO Closing on September 6, 2022 at an exercise price equal to the IPO price of $6.125 per share. The warrants were issued to the Trust on August 25, 2021 as consideration for the Trust's agreement to enter into an amendment to the Note Purchase Agreement to extend the maturity date of the Notes issued to the Trust under the Note Purchase Agreement from December 31, 2021 to May 31, 2022.

Referenced by the price of 1 transaction in Table II.

F14

Represents a right to purchase 4,896 shares of Common Stock underlying a warrant at an exercise price of $5.25 per share. The warrant was issued to Mr. Rubin on July 20, 2022 as consideration for his agreement to enter into an amendment to the Note Purchase Agreement to extend the maturity date of the Note issued to him under the Note Purchase Agreement from August 31, 2022 to October 31, 2022.

Referenced by the price of 1 transaction in Table II.

F15

Represents a right to purchase an aggregate of 163,248 shares of Common Stock underlying five warrants at an exercise price of $5.25 per share. The warrants were issued to the Trust on July 20, 2022 as consideration for the Trust's agreement to enter into an amendment to the Note Purchase Agreement to extend the maturity date of the Notes issued to the Trust under the Note Purchase Agreement from August 31, 2022 to October 31, 2022.

Referenced by the price of 1 transaction in Table II.

Remarks

Exhibit List - Exhibit 24.1: Power of Attorney (Gary D. Rubin) Exhibit 24.2: Power of Attorney (Harvey Sandler Revocable Trust)

Read the full filing on SEC EDGAR (opens in a new tab)